Glaukos reports record Q4 net sales $82.4M, up 16% YoY; FY2023 sales $314.7M, up 11%

GLAUKOS Corp

2023-FY EPS reported -$2.78 revenue$314,711,000

Record Q4 2023 net sales $82.4M, up 16% YoY; glaucoma $60.6M (+15%), corneal health $21.8M (+19%).
Q4 GAAP net loss $36.8M ($0.75/share) vs $31.5M ($0.66) YoY; non-GAAP loss $30.6M ($0.63).
Full-year 2023 net sales $314.7M, up 11% YoY; net loss $134.7M ($2.78/share) vs $99.2M ($2.09) in 2022.
Ended Q4 with $301M cash, equivalents & short-term investments; reaffirmed 2024 net sales guidance $350M-$360M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GLAUKOS Corp reported the fourth quarter and full year ended December 31, 2023 results: revenue $82.4 million, net income $36.8 million, EPS ($0.75) per diluted share. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $82.4 million
Net income: $36.8 million
EPS: ($0.75) per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: ● Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year on a constant currency basis. ● Glaucoma net sales of $60.6 million in Q4 2023 increased 15%

View on SEC.gov

Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-001431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.